These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18989660)

  • 21. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients?
    Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I
    Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder.
    Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E
    Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome.
    Hernandez CR; Smith GS; Houck PR; Pollock BG; Mulsant B; Dew MA; Reynolds CF
    Psychiatry Res; 2000 Dec; 97(1):41-9. PubMed ID: 11104856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personality change during depression treatment: a placebo-controlled trial.
    Tang TZ; DeRubeis RJ; Hollon SD; Amsterdam J; Shelton R; Schalet B
    Arch Gen Psychiatry; 2009 Dec; 66(12):1322-30. PubMed ID: 19996037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.
    Serretti A; Zanardi R; Cusin C; Rossini D; Lorenzi C; Smeraldi E
    Eur Neuropsychopharmacol; 2001 Oct; 11(5):375-80. PubMed ID: 11597824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between catechol-O-methyltransferase Val(108/158)Met polymorphism and psychotic features of bipolar disorder.
    Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E
    J Affect Disord; 2010 Sep; 125(1-3):341-4. PubMed ID: 20122740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and neurobiological effects of tianeptine and paroxetine in major depression.
    Nickel T; Sonntag A; Schill J; Zobel AW; Ackl N; Brunnauer A; Murck H; Ising M; Yassouridis A; Steiger A; Zihl J; Holsboer F
    J Clin Psychopharmacol; 2003 Apr; 23(2):155-68. PubMed ID: 12640217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence and interaction of genetic polymorphisms in catecholamine neurotransmitter systems and early life stress on antidepressant drug response.
    Xu Z; Zhang Z; Shi Y; Pu M; Yuan Y; Zhang X; Li L
    J Affect Disord; 2011 Sep; 133(1-2):165-73. PubMed ID: 21680027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between panic disorder and the L/L genotype of catechol-O-methyltransferase.
    Woo JM; Yoon KS; Choi YH; Oh KS; Lee YS; Yu BH
    J Psychiatr Res; 2004; 38(4):365-70. PubMed ID: 15203287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
    Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
    Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
    Gudayol-Ferré E; Herrera-Guzmán I; Camarena B; Cortés-Penagos C; Herrera-Abarca JE; Martínez-Medina P; Asbun-Bojalil J; Lira-Islas Y; Reyes-Ponce C; Guàrdia-Olmos J
    Hum Psychopharmacol; 2012 Nov; 27(6):577-86. PubMed ID: 24446536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Paroxetine versus clomipramine in female adolescents suffering from anorexia nervosa and depressive episode--a retrospective study on tolerability, reasons for discontinuing the antidepressive treatment and different outcome measurements].
    Strobel M; Warnke A; Roth M; Schulze U
    Z Kinder Jugendpsychiatr Psychother; 2004 Nov; 32(4):279-89. PubMed ID: 15565897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
    JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression.
    Mazeh D; Shahal B; Aviv A; Zemishlani H; Barak Y
    Int Clin Psychopharmacol; 2007 Nov; 22(6):371-5. PubMed ID: 17917556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.